Bassil Dahiyat, Xencor CEO
June 13, 2024 10:58 AM EDT
Deals
R&D

J&J re­turns bis­pe­cif­ic T cell en­gager to Xen­cor, re­duc­ing scope of part­ner­ship

Ayisha Sharma

News Reporter

John­son & John­son is hand­ing back a bis­pe­cif­ic T cell en­gager pro­gram to its part­ner Xen­cor, end­ing a sig­nif­i­cant piece of an agree­ment be­tween the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times